Arteris Inc

AIP remains in a Stage 4 decline with medium-term bearish bias as price forms lower highs and lower lows below declining EMAs. Short-term conditions are unfavorable, with price extended below EMAs and oversold. Execution is deferred, targeting a relief rally into the 9EMA/21EMA area for a structurally favorable sell opportunity.

• ↑Revenue $22.9M in Q1 2026, up 39% YoY; ACV+royalties at $92.8M.
• ↑Royalty revenue jumped 67% YoY to $7.9M; RPOs rose 33% to $118M.
• ↓Negative earnings yield and low book-to-price suggest overvaluation risk.